Industry news that matters to you.  Learn more

Archives for June 2014

Minomic to Register MiStat ELISA Prostate Cancer Test for CE Mark Approval

Australian biotechnology company Minomic International Limited will register its MiStat(TM) ELISA prostate cancer test for CE Mark approval in the latter part of 2014.

Assurex Health Releases Enhanced Pharmacogenomic Test to Help Clinicians Select Medications for Depression, Anxiety and PTSD

Assurex Health recently announced an enhancement of its GeneSight® Psychotropic test, providing clinicians with the most comprehensive genetic-based tool available to help them make individualized antidepressant and antipsychotic medication decisions for patients with depression, anxiety, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and other behavioral health disorders. GeneSight Psychotropic now covers 38 FDA-approved medications, including recently approved levomilnacipran (Fetzima®) and vortioxetine (Brintellix®).

Assurex Health Launches Comprehensive Genetic-Based Test to Help Clinicians Select Pain Medications for Patients

Assurex Health, Inc. recently announced a significant expansion of its GeneSight® Analgesic test.  The expanded test gives clinicians a multi-gene pharmacogenomics tool to guide medication decisions for patients with acute or chronic pain using patients’ own genetic profiles to help determine their potential response to 22 medications across four relevant medication classes: opioids, NSAIDs, muscle relaxants, and opioid dependency.

Targos Molecular Pathology GmbH and WuXi PharmaTech to Collaborate in Clinical Biomarker Services and Pathology Training in China

Targos GmbH, a leader in clinical biomarker services, and WuXi PharmaTech (NYSE:WX), a leading pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, recently announced a strategic biomarker collaboration.

HCG Announces New Standard-of-care for Cancer Treatment in India

HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care.